The results announced today from the fifth cohort of the RESOLVE trial, for treatment of EoE, are derived from 12, 4 mg injections of EP-104GI (total dose of 48 mg) administered to the lower ...

With a diverse drug portfolio and a robust pipeline of future drugs to market, this big pharma brand will play a major role ...

The Western medical establishment ousted him. China embraced him. Will the man on a mission to perform the first human head transplant ever pull it off?

At the California Poison Control System in San Francisco, a call has just come in from a mother whose toddler accidentally ...

Receiving an accurate diagnosis of Crohn’s disease and starting treatment right away is important to avoid ... and a camera ...

The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, ...

Eupraxia Pharmaceuticals (EPRX)announced additional positive clinical data from its RESOLVE Phase 1b/2a trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic ...

A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly – the ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new recommendations.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the third quarter 2024 and provided a business update. "The Mirum team executed ...

Reflects impairment of the goodwill and intangible assets recognized as a result of Illumina's acquisition of the Company in August 2021 ("the Acquisition"). GrowGeneration Corp. ("GrowGeneration," ...

Consisting of five separate booklets, the World Drug Report 2021 provides an in-depth analysis of the global drug markets and paints a comprehensive picture of the measurable effects and potential ...